CKb11 [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== CKb11 ======

The immunosuppressive [[tumor microenvironment]] (TME) of [[cancer]] strongly hinders the anti-tumor [[immune response]]s, thereby resulting in disappointing responses to [[immunotherapy]]. Chemoattractive and promotive traits of [[chemokine]]s exerted on [[leukocyte]]s have garnered interest in improving the efficiency of [[immunotherapy]] by increasing the infiltration of [[immune cell]]s in the TME. In a study, a [[folic acid]] (FA) -modified gene delivery system based on the self-assembly of DOTAP, MPEG-PCL-MPEG, and FA-PEG-PCL-PEG-FA, namely F-PPPD, was developed to deliver [[plasmid]]s encoding the immunostimulating chemokine [[CKb11]]. The delivery of plasmid CKb11 (pCKb11) by F-PPPD nanoparticles resulted in the high secretion of CKb11 from tumor cells, which successfully activated T cells, suppressed the M2 polarization of macrophages, promoted the maturation of [[dendritic cell]]s (DCs), facilitated the infiltration of [[natural killer cells]] and inhibited the infiltration of immunosuppressive cells in tumor tissues. Administration of F-PPPD/pCKb11 also significantly suppressed the cancer progression. The study demonstrated a [[nanotechnology]]-enabled delivery of pCKb11, that remodeled the immunosuppressive TME, for cancer treatment
((Nie W, Yu T, Liu X, Wang B, Li T, Wu Y, Zhou X, Ma L, Lin Y, Qian Z, Gao X. Non-viral vector mediated CKb11 with folic acid modification regulates macrophage polarization and DC maturation to elicit immune response against cancer. Bioact Mater. 2021 Apr 6;6(11):3678-3691. doi: 10.1016/j.bioactmat.2021.03.031. PMID: 33898872; PMCID: PMC8056185.)).